# Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

> **NCT02866370** · PHASE2 · UNKNOWN · sponsor: **NHS Greater Glasgow and Clyde** · enrollment: 120 (estimated)

## Conditions studied

- Ovarian Clear Cell Carcinoma
- Endometrial Clear Cell Carcinoma

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Paclitaxel
- **DRUG:** Pegylated Liposomal Doxorubicin (PLD)
- **DRUG:** Topotecan
- **DRUG:** Carboplatin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT02866370
- **Lead sponsor:** NHS Greater Glasgow and Clyde
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2020-03
- **Final completion:** 2021-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2016-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866370, "Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02866370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*